000 | 01977 a2200541 4500 | ||
---|---|---|---|
005 | 20250517163622.0 | ||
264 | 0 | _c20170814 | |
008 | 201708s 0 0 eng d | ||
022 | _a1096-0333 | ||
024 | 7 |
_a10.1016/j.taap.2017.07.006 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLi, Ting | |
245 | 0 | 0 |
_aNovel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. _h[electronic resource] |
260 |
_bToxicology and applied pharmacology _c09 2017 |
||
300 |
_a65-73 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
650 | 0 | 4 |
_aCell Cycle Proteins _xdrug effects |
650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
650 | 0 | 4 |
_aChaperonins _xdrug effects |
650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
650 | 0 | 4 |
_aEverolimus _xpharmacology |
650 | 0 | 4 |
_aHSP90 Heat-Shock Proteins _xantagonists & inhibitors |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunosuppressive Agents _xpharmacology |
650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
650 | 0 | 4 |
_aOncogene Protein v-akt _xantagonists & inhibitors |
650 | 0 | 4 | _aReceptor, IGF Type 1 |
650 | 0 | 4 |
_aReceptors, Somatomedin _xantagonists & inhibitors |
650 | 0 | 4 |
_aSaponins _xtoxicity |
650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
650 | 0 | 4 |
_aTriterpenes _xtoxicity |
700 | 1 | _aChen, Xin | |
700 | 1 | _aDai, Xiao-Yang | |
700 | 1 | _aWei, Bin | |
700 | 1 | _aWeng, Qin-Jie | |
700 | 1 | _aChen, Xiuping | |
700 | 1 | _aOuyang, De-Fang | |
700 | 1 | _aYan, Ru | |
700 | 1 | _aHuang, Zhang-Jian | |
700 | 1 | _aJiang, Hu-Lin | |
700 | 1 | _aZhu, Hong | |
700 | 1 | _aLu, Jin-Jian | |
773 | 0 |
_tToxicology and applied pharmacology _gvol. 330 _gp. 65-73 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.taap.2017.07.006 _zAvailable from publisher's website |
999 |
_c27371430 _d27371430 |